M. Ricci

发表

FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma

Richard Pazdur, Robert Justice, Nitin Mehrotra, 2015, Clinical Cancer Research.

Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death.

K. Flaherty, W. El-Deiry, D. Dicker, 2007, Cancer cell.

Regulatory Considerations in the Development of Monoclonal Antibodies for Diagnosis and Therapy

Patrick G. Swann, P. Swann, M. Ricci, 2014 .

Estrogen Receptor Reduces CYP1A1 Induction in Cultured Human Endometrial Cells*

C. Mattingly, W. A. Toscano, M. Ricci, 1999, The Journal of Biological Chemistry.

Mxi1 is induced by hypoxia in a HIF-1–dependent manner and protects cells from c-Myc-induced apoptosis

W. El-Deiry, D. Dicker, P. Corn, 2005, Cancer biology & therapy.

Dysregulated ΔNp63α Inhibits Expression of Ink4a/arf, Blocks Senescence, and Promotes Malignant Conversion of Keratinocytes

S. Jay, M. Ricci, W. Weinberg, 2011, PloS one.

Path to Market Approval: Regulatory Perspective of ADC Nonclinical Safety Assessments

M. Ricci, R. A. Claro, Natalie E. Simpson, 2016 .

Regulatory aspects of oncology drug safety evaluation: past practice, current issues, and the challenge of new drugs.

H. Rosenfeldt, K. Benson, M. Ricci, 2010, Toxicology and applied pharmacology.

Supplemental Data Reduction of TRAIL-Induced Mcl-1 and cIAP 2 by c-Myc or Sorafenib Sensitizes Resistant Human Cancer Cells to TRAIL-Induced Death

K. Flaherty, D. Dicker, Wenge Wang, 2007 .

Mcl-1: a gateway to TRAIL sensitization.

W. El-Deiry, Seok-Hyun Kim, M. Ricci, 2008, Cancer research.

Choice of Starting Dose for Biopharmaceuticals in First-in-Human Phase I Cancer Clinical Trials.

L. Siu, A. Hansen, L. Roskos, 2014, The oncologist.

ChoiceofStartingDoseforBiopharmaceuticalsinFirst-in-HumanPhase I Cancer Clinical Trials

L. Siu, A. Hansen, L. Roskos, 2015 .

I mmunotherapy, M onoclonals, and V accines Chemotherapeutic Approaches for Targeting Cell Death Pathways

W. Zong, M. Ricci, 2017 .

Specific Enzyme-Linked Immunosorbent Assays for Quantitation of Antibody-Cytokine Fusion Proteins

S. Gillies, J. Hank, P. Sondel, 1999, Clinical Diagnostic Laboratory Immunology.

Chemotherapeutic approaches for targeting cell death pathways.

W. Zong, Wei-Xing Zong, M. Ricci, 2006, The oncologist.

Direct Repression of FLIP Expression by c-myc Is a Major Determinant of TRAIL Sensitivity

W. El-Deiry, D. Dicker, Duonan Yu, 2004, Molecular and Cellular Biology.

Bax is a transcriptional target and mediator of c-myc-induced apoptosis.

John Calvin Reed, W. El-Deiry, T. Miyashita, 2000, Cancer research.

The Extrinsic Pathway of Apoptosis

W. El-Deiry, M. Ricci, 2007 .

2 The Extrinsic Pathway of Apoptosis

W. El-Deiry, M. Ricci, 2007 .

Cell death pathway characteristics Apoptosis Autophagy Necrosis Senescence Mitotic catastrophe Morphologic changes Cell membrane

M. Ricci, Wei-Xing Zongb, 2006 .

Modulation of TRAIL-induced tumor cell apoptosis in a hypoxic environment

W. El-Deiry, D. Dicker, L. Campbell, 2005, Cancer biology & therapy.

Chemotherapy-resistant side-population of colon cancer cells has a higher sensitivity to TRAIL than the Non-SP, a higher expression of c-Myc and TRAIL-receptor DR4

Shi-Yong Sun, W. El-Deiry, Robyn T. Sussman, 2007, Cancer biology & therapy.

Pharmacokinetics and stability of the ch14.18–interleukin-2 fusion protein in mice

S. Gillies, M. Super, J. Hank, 1999, Cancer Immunology, Immunotherapy.

ECC-1 human endometrial cells as a model system to study dioxin disruption of steroid hormone function

W. A. Toscano, M. Ricci, D. G. Toscano, 1999, In Vitro Cellular & Developmental Biology - Animal.

FDA's Approach to Regulating Biosimilars

Richard Pazdur, P. Keegan, Amy McKee, 2016, Clinical Cancer Research.